PRPH

ProPhase Labs, Inc. is a biotech, genomics, and consumer products company. The Company is engaged in providing whole genome sequencing solutions, diagnostic development, such as its potentially life-saving test for the early detection of esophageal cancer and a direct-to-consumer marketing platform for OTC dietary supplements. It develops, manufactures, and commercializes health and wellness solutions. Its Diagnostic services segment provides diagnostic information services to a range of customers in the United States, including health plans, third-party payers and government organizations. Its Consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and provides personal genomics products and services. The Company also develops and markets dietary supplements under the TK Supplement brand, which includes Legendz XL and Triple Edge XL.

Wall Street analysts forecast PRPH stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for PRPH is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Prophase Labs Inc revenue for the last quarter amounts to 883.00K USD, decreased -37.64 % YoY.

Prophase Labs Inc. EPS for the last quarter amounts to -0.16 USD, decreased -54.29 % YoY.

Prophase Labs Inc (PRPH) has 96 emplpoyees as of December 16 2025.

Today PRPH has the market capitalization of 5.22M USD.